KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Accured Expenses (2024 - 2026)

AbCellera Biologics filings provide 3 years of Change in Accured Expenses readings, the most recent being -$9.4 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 175.92% to -$9.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Mar 2026, down 120.98% year-over-year, with the annual reading at $3.5 million for FY2025, 67.49% down from the prior year.
  • Change in Accured Expenses hit -$9.4 million in Q1 2026 for AbCellera Biologics, down from $5.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.6 million in Q4 2024 and bottomed at -$9.4 million in Q1 2026.
  • Average Change in Accured Expenses over 3 years is $520666.7, with a median of $4.1 million recorded in 2024.
  • Peak annual rise in Change in Accured Expenses hit 30.11% in 2025, while the deepest fall reached 183.13% in 2025.
  • AbCellera Biologics' Change in Accured Expenses stood at $6.6 million in 2024, then dropped by 13.21% to $5.7 million in 2025, then crashed by 263.78% to -$9.4 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Change in Accured Expenses are -$9.4 million (Q1 2026), $5.7 million (Q4 2025), and $5.1 million (Q3 2025).